Immune mechanisms that promote S. aureus persistence during craniotomy-associated biofilm infection

开颅手术相关生物膜感染期间促进金黄色葡萄球菌持续存在的免疫机制

基本信息

  • 批准号:
    9896877
  • 负责人:
  • 金额:
    $ 41.22万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-05-15 至 2023-03-31
  • 项目状态:
    已结题

项目摘要

Neurosurgery to relieve life-threatening edema (decompressive craniectomy) or gain temporary access to the brain for tumor resection (craniotomy) requires removal of a portion of the skull (i.e. bone flap). The infection incidence after craniotomy/craniectomy ranges from 0.8-12%, with a significant number caused by methicillin- resistant S. aureus (MRSA), which forms a biofilm on both surfaces of the bone flap. Biofilms are bacterial communities encased in a self-produced matrix that are recalcitrant to antibiotics due to their metabolic dormancy. Our laboratory has developed a mouse model of S. aureus craniotomy-associated biofilm infection that shares important ultrastructural and MRI attributes with human disease, which can be exploited to identify mechanisms for infection persistence. We have identified a unique immune compartmentalization in the S. aureus craniotomy model, namely preferential neutrophil (PMN) recruitment and chemokine expression in the subcutaneous galea, whereas monocytes are more prominent in the brain. Myeloid-derived suppressor cells (MDSCs), an immature granulocyte population with anti-inflammatory properties, are present in both compartments, but most abundant in the galea. Our preliminary studies have identified a role for IL-10 in promoting S. aureus survival in both the galea and brain, suggesting that IL-10 may be critical for programming glia and infiltrating leukocytes towards an anti-inflammatory state to promote biofilm persistence. Although IL- 10 is expressed in both the galea and brain, the cytokine is poised to inhibit the antibacterial activity of cell types that are enriched at either site, namely PMNs and MDSCs (galea) vs. microglia, astrocytes, and monocytes (brain). In terms of molecular mechanisms, our preliminary data demonstrate that S. aureus- derived lactate induces IL-10 production in MDSCs. Since lactate is a histone deacetylase inhibitor (HDACi) and the IL-10 promoter is regulated by histone acetylation, this supports the hypothesis that S. aureus biofilm- derived lactate is an exogenous HDACi that promotes IL-10 expression and inhibits antimicrobial responses in the galea and brain by targeting MDSCs/PMNs vs. microglia/astrocytes/monocytes, respectively, to promote infection persistence. The crosstalk between IL-10 and galeal vs. brain populations and the molecular mechanisms responsible for this compartmentalized specificity will be tested in the following Specific Aims. 1) Identify the role of MDSC-derived IL-10 on PMN antimicrobial activity in the galea during S. aureus craniotomy- associated biofilm infection; 2) Determine whether IL-10 promotes S. aureus persistence in the brain during craniotomy-associated biofilm infections by polarizing glia and monocytes towards an anti-inflammatory state; and 3) Establish that S. aureus biofilm-derived lactate enhances IL-10 production by inhibiting HDAC activity. An improved understanding of the immune compartmentalization during craniotomy biofilm infection may be leveraged to enhance antimicrobial activity and biofilm clearance in both the galea and brain. Our findings suggest that IL-10 represents an attractive candidate to explore for this purpose.
神经外科手术,以减轻危及生命的水肿(去骨瓣减压术)或获得临时进入 用于肿瘤切除术(开颅术)的脑需要移除颅骨的一部分(即骨瓣)。感染 开颅术/颅骨切除术后的发病率范围为0.8- 12%,其中大量是由甲氧西林引起的, 耐甲氧西林金黄色葡萄金黄色葡萄球菌(MRSA),其在骨瓣的两个表面上形成生物膜。生物膜是细菌 由于它们的新陈代谢, 休眠本实验室建立了一种S.金黄色葡萄球菌开颅相关生物膜感染 它与人类疾病具有重要的超微结构和MRI属性,可用于识别 感染持久性的机制。我们已经确定了一个独特的免疫区室化的S。 金黄色葡萄球菌开颅模型,即优先中性粒细胞(PMN)募集和趋化因子表达, 皮下帽状细胞,而单核细胞在大脑中更突出。髓源性抑制细胞 MDSC是一种具有抗炎特性的未成熟粒细胞群, 隔间,但最丰富的盔瓣。我们的初步研究已经确定了IL-10在 促进S.金黄色葡萄球菌在帽状软骨和大脑中的存活,表明IL-10可能对编程至关重要, 神经胶质细胞和浸润的白细胞朝向抗炎状态以促进生物膜持久性。虽然, 10在帽状软骨和脑中表达,该细胞因子准备抑制细胞的抗菌活性, 在任一位点富集的类型,即PMN和MDSC(帽状细胞)与小胶质细胞、星形胶质细胞和 单核细胞(脑)。在分子机制方面,我们的初步数据表明,S。金黄色, 衍生的乳酸盐诱导MDSC中的IL-10产生。由于乳酸是组蛋白去乙酰化酶抑制剂(HDACi), IL-10启动子受组蛋白乙酰化调控,支持S.金黄色葡萄球菌生物膜 衍生的乳酸盐是一种外源性HDACi,其促进IL-10表达并抑制抗微生物应答, 通过分别靶向MDSC/PMN与小胶质细胞/星形胶质细胞/单核细胞,促进 感染持续性IL-10和帽状细胞与脑细胞群之间的串扰以及分子生物学效应。 将在以下特定目的中测试负责这种区室化特异性的机制。第一章 鉴定MDSC衍生的IL-10对S.金耳开颅术- 相关生物膜感染; 2)确定IL-10是否促进S.金黄色葡萄球菌在大脑中的持久性, 通过使神经胶质细胞和单核细胞向抗炎状态极化的开颅术相关的生物膜感染; (3)建立S.金黄色葡萄球菌生物膜衍生的乳酸盐通过抑制HDAC活性增强IL-10产生。 对开颅手术生物膜感染期间免疫区室化的更好理解可能是 用于增强帽状体和脑中的抗微生物活性和生物膜清除。我们的研究结果 表明IL-10代表了用于该目的探索的有吸引力的候选物。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Tammy L Kielian其他文献

Tammy L Kielian的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Tammy L Kielian', 18)}}的其他基金

Modulating granulocytic myeloid-derived suppressor cell (G-MDSC) metabolic activity to promote Staphylococcus aureus biofilm clearance
调节粒细胞骨髓源性抑制细胞 (G-MDSC) 代谢活性以促进金黄色葡萄球菌生物膜清除
  • 批准号:
    10738662
  • 财政年份:
    2023
  • 资助金额:
    $ 41.22万
  • 项目类别:
T cell-innate immune crosstalk regulates Staphylococcus aureus craniotomy infection
T细胞先天免疫串扰调节金黄色葡萄球菌开颅感染
  • 批准号:
    10590634
  • 财政年份:
    2022
  • 资助金额:
    $ 41.22万
  • 项目类别:
Immune mechanisms that promote S. aureus persistence during craniotomy-associated biofilm infection
开颅手术相关生物膜感染期间促进金黄色葡萄球菌持续存在的免疫机制
  • 批准号:
    10375439
  • 财政年份:
    2018
  • 资助金额:
    $ 41.22万
  • 项目类别:
Therapeutic targeting of aberrant glial function during Juvenile Batten Disease
幼年巴顿病期间异常神经胶质功能的治疗靶向
  • 批准号:
    8660113
  • 财政年份:
    2014
  • 资助金额:
    $ 41.22万
  • 项目类别:
Therapeutic targeting of aberrant glial function during Juvenile Batten Disease
幼年巴顿病期间异常神经胶质功能的治疗靶向
  • 批准号:
    8788453
  • 财政年份:
    2014
  • 资助金额:
    $ 41.22万
  • 项目类别:
Contribution of extracellular enzymes to Staphylococcus aureus biofilm development
胞外酶对金黄色葡萄球菌生物膜发育的贡献
  • 批准号:
    10665029
  • 财政年份:
    2009
  • 资助金额:
    $ 41.22万
  • 项目类别:
Innate Immunity to S. aureus biofilm
对金黄色葡萄球菌生物膜的先天免疫
  • 批准号:
    7750241
  • 财政年份:
    2009
  • 资助金额:
    $ 41.22万
  • 项目类别:
The Role of Nuclease in Biofilm Development and Disease
核酸酶在生物膜发育和疾病中的作用
  • 批准号:
    7750239
  • 财政年份:
    2009
  • 资助金额:
    $ 41.22万
  • 项目类别:
Innate Immune Response to S. aureus Biofilm
对金黄色葡萄球菌生物膜的先天免疫反应
  • 批准号:
    10665032
  • 财政年份:
    2009
  • 资助金额:
    $ 41.22万
  • 项目类别:
Contribution of extracellular enzymes to Staphylococcus aureus biofilm development
胞外酶对金黄色葡萄球菌生物膜发育的贡献
  • 批准号:
    10461797
  • 财政年份:
    2009
  • 资助金额:
    $ 41.22万
  • 项目类别:

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 41.22万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 41.22万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 41.22万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 41.22万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 41.22万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 41.22万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 41.22万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 41.22万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 41.22万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 41.22万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了